| scholarly article | Q13442814 |
| P2093 | author name string | Ornella Piazza | |
| Geremia Zito Marinosci | |||
| Giuseppe De Benedictis | |||
| David D'Auria | |||
| P2860 | cites work | Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial | Q28203758 |
| Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist | Q28316514 | ||
| Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist | Q28379390 | ||
| Molecular pharmacology of human vasopressin receptors | Q30636532 | ||
| VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist | Q33534908 | ||
| Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study | Q33712822 | ||
| Age and gender as risk factors for hyponatremia and hypernatremia | Q33973244 | ||
| Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial | Q34003169 | ||
| Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure | Q34101478 | ||
| Aquaporins in the kidney: from molecules to medicine | Q34107691 | ||
| Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia | Q34581679 | ||
| Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist | Q34663375 | ||
| Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial | Q34782162 | ||
| Evaluation and management of hypo-osmolality in hospitalized patients | Q35151414 | ||
| Salt and water: a simple approach to hyponatremia | Q35646409 | ||
| Consequences of inadequate management of hyponatremia | Q36138277 | ||
| Vasopressin antagonists: role in the management of hyponatremia | Q36534664 | ||
| Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study | Q38496208 | ||
| Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. | Q40890191 | ||
| Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications | Q41174860 | ||
| Conivaptan and its role in the treatment of hyponatremia | Q42108467 | ||
| OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. | Q42537393 | ||
| Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury | Q42694389 | ||
| Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients | Q43010100 | ||
| Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis | Q43028395 | ||
| A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial | Q44261207 | ||
| Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial | Q44387826 | ||
| Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia | Q46213573 | ||
| Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia | Q46979676 | ||
| Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree | Q48306958 | ||
| Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. | Q50947709 | ||
| Nephrogenic syndrome of inappropriate antidiuresis | Q55670717 | ||
| Hyponatremia | Q56453470 | ||
| Vasopressin V2 Receptor Blockade With Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia | Q56765793 | ||
| Characterization and Prognostic Value of Persistent Hyponatremia in Patients With Severe Heart Failure in the ESCAPE Trial | Q57630871 | ||
| Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea | Q71229604 | ||
| Management of hyponatremia | Q80144135 | ||
| When is it appropriate to use vasopressin receptor antagonists? | Q80862549 | ||
| Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management | Q81159759 | ||
| Binding Sites for Vasopressin in the Human Pituitary are Associated with Corticotrophs and may Differ from Other Known Vasopressin Receptors | Q83344720 | ||
| Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia | Q83942284 | ||
| The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options | Q84372069 | ||
| P921 | main subject | hyponatremia | Q824292 |
| P304 | page(s) | 1-14 | |
| P577 | publication date | 2012-04-30 | |
| P1433 | published in | Translational medicine @ UniSa | Q27724979 |
| P1476 | title | Vaptans and hyponatremia in critical patients | |
| P478 | volume | 3 |
| Q35746536 | Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice |
| Q90310405 | Brain Derived Neurotrophic Factor and Supraoptic Vasopressin Neurons in Hyponatremia |
| Q42740385 | Dopamine Use in Intensive Care: Are We Ready to Turn it Down? |
| Q38780288 | Tolvaptan utilization in children with chronic hyponatremia due to inappropriate antidiuretic hormone secretion (SIADH). Three case reports and review of the literature |
Search more.